Genetics Testing

Illumina Board Under Siege by Carl Icahn

“Illumina’s acquisition of GRAIL seems to have fallen through which means they wasted a great deal of resources as a result of consistently bad decision-making.” That’s the conclusion we reached six months ago in an article on Illumina (ILMN) titled, Illumina Stock Falls on GRAIL Acquisition Fail. While we typically check in with our stocks […]

Checking in With Oxford Nanopore Stock

Regular readers know that we don’t get distracted or unnerved by dropping stock prices. It’s natural to feel a bit panicky. You know how many of our article titles on gene-sequencing stocks last year were variations on: “XXX Stock Plummets: Why We’re Not Jumping to Our Death?” About 15% of our Nanalyze Disruptive Tech Portfolio […]

Falling Out of Love With Invitae Stock

People always ask Google for stock price predictions as if someone actually knows. They’re making a fundamental mistake newbies often make – investing in stocks instead of companies. The only thing we can be certain of is the old adage, “it’s about time in the market, not timing the market.” That’s provided you’re investing in […]

Natera Stock Expands into Cancer Blood Testing

To say it’s been a tough year for retail investors would be an understatement. That’s especially true for technology stocks, with the Nasdaq down 35% for the year compared to about a 20% drop for the S&P 500. Interestingly, biotech stocks haven’t done as bad, based on the broad NASDAQ Biotechnology Index (NBI), which currently […]

CareDx Stock is Pure Play on Organ Transplant Diagnostics

You know those pop TV shows that ask burning questions like, “Where are they now?” Usually, the episode will pick some child star who flamed out early, spending the better part of their youth burning through rerun royalties with drugs and alcohol. Today, little Johnny Boy is three years sober and doing a podcast interviewing […]

Illumina Stock Falls on GRAIL Acquisition Fail

Unless you can watch your stock holding decline by 50% without becoming panic-stricken, you should not be in the stock market,” says Warren Buffet. That advice couldn’t be more applicable today as the bear market continues to hit new lows. To feel comfortable with your portfolio in the red, you need to invest in quality […]

Is Fulgent Genetics Stock More Than a One-Hit Wonder?

Our MBAs at Nanalyze are constantly tweaking our disruptive tech investing methodology, adapting our metrics as we play through one of the weirdest post-bull runs in Wall Street history – and that’s saying a lot. Gone are the days of growth at all costs, but that’s been the mantra of the tech sector for a […]

Here’s Why Invitae Stock Can’t Stop Falling

Loss aversion is a psychological concept where humans are shown to feel the pain of loss twice as much as the joy of gain. Even the perception of loss can result in pain. That’s why investors sweat paper losses when they haven’t actually lost anything. Over the past six months, shares of Invitae (NVTA) have […]

FOXO Technologies Stock: Investing in Longevity Insurance

Getting life insurance is one of those things that responsible adults are supposed to do, like work the same job for 45 years and retire with a gold watch. Who does that anymore? Similarly, the number of people buying into life insurance policies is dropping. Over the last decade, life insurance market penetration decreased by […]

Myriad Genetics Stock vs. Invitae Stock

If you stick your neck out and make a long-term call on a stock that turns out to be right, expect to hear nothing but crickets years later when you’re proven right. If your call turns out to be wrong, people will be lining up around the block to point out what an idiotic buffoon […]